Thiazolidinediones May Not Reduce Diabetes Incidence in Type 1 Diabetes

Shigihara, Toshikatsu; Okubo, Yoshiaki; Kanazawa, Yasuhiko; Oikawa, Yoichi; Shimada, Akira

doi:10.1196/annals.1375.056

Cited by 6 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our negative findings are supported by Shigihara et al (15) who showed no improvement in insulitis or cytokine profile in NOD mice treated with pioglitazone when compared to metformin. Similarly, Zdravkovic et al (16) failed to show improvement in HbA1c or a decrease in insulin requirements in obese adolescents with T1DM treated with pioglitazone.…”

Section: Discussionsupporting

confidence: 82%

Effect of Pioglitazone on the Course of New-Onset Type 1 Diabetes Mellitus

Tafuri¹,

Godil²,

Lane³

et al. 2013

JCRPE

View full text Add to dashboard Cite

Objective: Type 1 diabetes mellitus (T1DM) is caused by insulin deficiency resulting from progressive destruction of β cells. The histological hallmark of the diabetic islet is mononuclear cell infiltration. Thiazolidinediones (TZDs) activate PPARg and enhance the actions of insulin. Studies in non-obese diabetic and streptocotozin-treated mouse models demonstrated that pretreatment with TZDs prevented the development of T1DM. The purpose of this study was to examine whether pioglitazone, given with insulin, preserved β cell function in patients with new-onset T1DM.Methods: This was a randomized, double-blind, placebo-controlled 24-week study. Subjects received pioglitazone or placebo. Blood sugar, glycated hemoglobin (HbA1c), C-peptide, and liver enzymes were measured at baseline. Boost© stimulated C-peptide responses were measured at baseline and at 24 weeks. Blood sugar, insulin dose, height, weight, and liver enzymes were monitored at each visit. HbA1c was performed every 12 weeks.Results: Of the 15 patients, 8 received pioglitazone, and 7 - placebo. There was no clinical improvement in HbA1c between or within groups at the completion of the study. Mean peak C-peptide values were similar between groups at baseline. Mean peak C-peptide level was slightly higher at 24 weeks in the pioglitazone group compared to the placebo (1.8 vs. 1.5ng/mL) which was considered as clinically insignificant. The interaction of HbA1c and insulin dose (HbA1c* insulin/kg/day), which combines degree of diabetic control and dose of insulin required to achieve this control, showed transient improvement in the pioglitazone group at 12 weeks but was not sustained at 24 weeks.Conclusion: In this pilot study, pioglitazone did not preserve β cell function when compared to placebo.Conflict of interest:None declared.

show abstract

Section: Discussionsupporting

confidence: 82%